Surrozen, Inc. (SRZN) Bundle
An Overview of Surrozen, Inc. (SRZN)
General Summary of Surrozen, Inc. (SRZN)
Surrozen, Inc. is a clinical-stage biotechnology company established in 2015, headquartered in South San Francisco, California. The company is focused on discovering and developing drug candidates that selectively modulate the Wnt pathway, which is essential for tissue repair across various organs. Surrozen has developed a unique platform for Wnt therapeutics and operates through its wholly-owned subsidiary, Surrozen Netherlands, B.V., incorporated in 2022.
As of 2024, Surrozen's primary product candidates include:
- SZN-043: A candidate targeting tissue repair in various organs.
- SZN-8141: A product candidate aimed at treating diabetic macular edema and age-related macular degeneration.
- SZN-8143: A combination therapy for multiple ophthalmology indications.
- SZN-113: Targeting Fuchs’ endothelial corneal dystrophy and geographic atrophy.
In terms of sales, the company reported collaboration and license revenue of $10 million for the nine months ending September 30, 2024, attributed to a milestone achievement under their collaboration agreement.
Company's Financial Performance in the Latest Financial Reports
Surrozen's financial performance for the nine months ending September 30, 2024, indicates a significant milestone in revenue generation. The company reported total collaboration and license revenue of $10 million, a substantial increase compared to $0 in the same period of 2023.
Operating expenses for the nine-month period were $26.9 million, a decrease of 25% from $36.1 million in the prior year. This decrease is primarily due to reductions in research and development costs, which fell from $21.1 million to $15.8 million. The breakdown of research and development expenses is as follows:
| Program | 2024 Expenses ($) | 2023 Expenses ($) | Change ($) | Change (%) |
|---|---|---|---|---|
| SZN-043 | 8,162 | 8,520 | (358) | -4% |
| SZN-1326 | 1,295 | 4,522 | (3,227) | -71% |
| Discovery and preclinical programs | 6,325 | 8,093 | (1,768) | -22% |
| Total R&D Expenses | 15,782 | 21,135 | (5,353) | -25% |
Despite the revenue increase, the company reported a net loss of $35.5 million for the nine months ended September 30, 2024, compared to a net loss of $34.1 million for the same period in 2023. Cash and cash equivalents stood at $31 million as of September 30, 2024.
Surrozen as a Leader in the Industry
Surrozen, Inc. is positioned as a leader in the biotechnology sector, particularly in the development of Wnt pathway modulators. The company's innovative approach to tissue repair and its advancements in ophthalmology treatments set it apart in a competitive landscape. The successful achievement of revenue milestones and a robust pipeline of product candidates illustrate Surrozen's potential for growth and impact in the biotechnology industry. Investors and stakeholders are encouraged to explore Surrozen's strategies and innovations further to understand the factors contributing to its success.
Mission Statement of Surrozen, Inc. (SRZN)
Mission Statement Overview
Surrozen, Inc. (SRZN) aims to discover and develop innovative drug candidates that selectively modulate the Wnt pathway, which is critical for tissue repair across various organs and tissues. This mission reflects the company's commitment to addressing unmet medical needs through scientific advancement and therapeutic innovation.
Core Component 1: Innovation in Drug Development
The mission emphasizes the importance of innovation in the development of drug candidates. Surrozen’s focus on the Wnt pathway positions it to pioneer therapies that may significantly improve outcomes for patients with various diseases. For instance, the company’s lead product candidate, SZN-043, is currently undergoing clinical trials aimed at treating conditions such as diabetic macular edema and age-related macular degeneration.
As of September 30, 2024, Surrozen reported a net loss of $35.5 million for the nine months ended, which highlights substantial investments in research and development to advance its innovative pipeline.
Core Component 2: Addressing Unmet Medical Needs
Surrozen’s mission is driven by the goal of addressing significant unmet medical needs. The company is focused on developing therapies for conditions that currently lack effective treatments. The ongoing clinical study of SZN-043 exemplifies this commitment, targeting conditions that affect millions globally.
In the nine months ended September 30, 2024, Surrozen's research and development expenses totaled $15.8 million, reflecting its dedication to advancing these critical therapies.
Core Component 3: Commitment to Quality and Efficacy
The mission statement underscores Surrozen’s commitment to quality and efficacy in its drug development processes. The company aims to ensure that its therapies not only meet regulatory standards but also provide meaningful benefits to patients. This is evident in the stringent clinical trial protocols being followed for SZN-043 and other candidates.
As of September 30, 2024, Surrozen reported cash and cash equivalents of $31 million, which it anticipates will support operations for at least the next 12 months, reflecting a strategic approach to maintaining quality while managing financial resources effectively.
| Metrics | Q3 2024 | Q3 2023 | Change (%) |
|---|---|---|---|
| Net Loss | $1.4 million | $10.4 million | -86% |
| R&D Expenses | $15.8 million | $21.1 million | -25% |
| Cash and Cash Equivalents | $31 million | $34.4 million | -10.3% |
Vision Statement of Surrozen, Inc. (SRZN)
Vision Statement Overview
The vision statement of Surrozen, Inc. (SRZN) focuses on pioneering advancements in the biotechnology sector, particularly in the modulation of the Wnt pathway for enhancing tissue repair across various organs. As of 2024, the company emphasizes its commitment to innovation and excellence in therapeutic development.
Commitment to Innovation
Surrozen aims to transform the biotechnology landscape through innovative research and development. The company is dedicated to discovering and optimizing drug candidates that leverage the Wnt pathway, which plays a crucial role in tissue regeneration. In the nine months ended September 30, 2024, Surrozen recorded collaboration and license revenue of $10 million, indicating robust strategic partnerships that enhance its innovation capacity .
Focus on Clinical Development
As part of its vision, Surrozen prioritizes advancing its clinical programs. The total research and development expenses for the nine months ended September 30, 2024, were $15.8 million, reflecting a 25% decrease from the previous year due to streamlined operations and a focus on clinical-stage programs . The company's leading candidate, SZN-043, is currently undergoing clinical trials, demonstrating its commitment to bringing innovative therapies to market.
Global Impact and Accessibility
Surrozen envisions a future where its therapies are accessible globally, addressing significant unmet medical needs. The company’s focus on developing treatments for conditions like diabetic macular edema and age-related macular degeneration aligns with its mission to improve patient outcomes worldwide. As of September 30, 2024, Surrozen held cash and cash equivalents of $31 million, which supports its ongoing clinical trials and operational needs .
Strategic Collaborations
Collaboration is a cornerstone of Surrozen's strategy to achieve its vision. The company has engaged in strategic partnerships that not only bolster its research capabilities but also facilitate the commercialization of its products. For instance, the collaboration with TCGFB, Inc. is expected to yield up to $6 million in research funding over two years . Such collaborations are critical for enhancing the company’s pipeline and accelerating the development of its drug candidates.
Financial Sustainability
Surrozen is focused on maintaining financial sustainability while pursuing its vision. The company incurred a net loss of $35.5 million during the nine months ended September 30, 2024, primarily due to ongoing R&D investments . However, with a strategic plan to secure additional funding through equity offerings and collaborations, Surrozen aims to stabilize its financial position and continue its growth trajectory.
| Financial Metrics | 2024 (9 Months Ended Sept 30) | 2023 (9 Months Ended Sept 30) | Change (%) |
|---|---|---|---|
| Collaboration and License Revenue | $10,000,000 | $0 | |
| Total R&D Expenses | $15,782,000 | $21,135,000 | -25% |
| Net Loss | $35,525,000 | $34,129,000 | 4% |
| Cash and Cash Equivalents | $31,000,000 | $33,975,000 | -8.7% |
Conclusion
Surrozen's vision for 2024 reflects its commitment to innovation, clinical excellence, and global impact. Through strategic collaborations and a focus on financial sustainability, the company is poised to make significant contributions to the biotechnology field, particularly in tissue repair therapies.
Core Values of Surrozen, Inc. (SRZN)
Innovation
Innovation is at the heart of Surrozen, Inc.'s operational ethos. The company is committed to advancing drug discovery and development through innovative approaches that selectively modulate the Wnt pathway. This commitment is essential for addressing unmet medical needs across various therapeutic areas.
In 2024, Surrozen has made significant strides in its research and development efforts. For instance, the company is advancing multiple product candidates, including SZN-043, which is currently undergoing clinical trials. The investment in research and development for the nine months ended September 30, 2024, was approximately $15.8 million, reflecting a continued focus on innovation despite overall operational losses.
Integrity
Integrity is a core value that Surrozen embodies in all its interactions and business practices. This value is crucial for maintaining trust with stakeholders, including investors, employees, and partners.
Surrozen upholds integrity through transparent reporting and compliance with regulatory standards. For example, in its financial disclosures for the period ending September 30, 2024, the company reported an accumulated deficit of approximately $257.2 million and total stockholders' equity of $5.67 million. This transparency allows stakeholders to make informed decisions based on the company's financial health.
Collaboration
Collaboration is a key value that Surrozen promotes to harness collective expertise in the biotechnology sector. The company believes that strategic partnerships enhance its capabilities in drug development and commercialization.
In 2024, Surrozen entered into a strategic research collaboration with TCGFB, Inc. This partnership aims to discover antibody therapeutics targeting TGF-β for idiopathic pulmonary fibrosis, with the potential to generate up to $6 million in revenue. Such collaborations not only expand Surrozen’s research portfolio but also strengthen its position in the industry.
Excellence
Excellence is a guiding principle that drives Surrozen to achieve high standards in every aspect of its operations. The company is dedicated to delivering top-tier research results and therapeutic solutions.
As of September 30, 2024, Surrozen reported collaboration and license revenue of $10 million, a significant achievement that underscores its commitment to excellence in its business endeavors. The company's focus on quality is evident in its ongoing clinical trials and the rigorous protocols it follows in research and development.
Accountability
Accountability is a fundamental value at Surrozen, ensuring that the company remains responsible for its actions and outcomes. This value fosters a culture of ownership among employees and management alike.
Surrozen's management is actively involved in monitoring the company's financial performance, as evidenced by the reported net loss of $35.5 million for the nine months ended September 30, 2024. The leadership's accountability extends to its commitment to operational efficiency and strategic resource allocation to mitigate losses and achieve profitability in the future.
| Core Value | Description | 2024 Key Metrics |
|---|---|---|
| Innovation | Advancement in drug discovery and development. | R&D Investment: $15.8 million |
| Integrity | Transparency and compliance in operations. | Accumulated Deficit: $257.2 million |
| Collaboration | Strategic partnerships to enhance capabilities. | Collaboration Revenue: $10 million |
| Excellence | High standards in research and operations. | Collaboration and License Revenue: $10 million |
| Accountability | Responsibility for actions and outcomes. | Net Loss: $35.5 million |
Surrozen, Inc. (SRZN) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Surrozen, Inc. (SRZN) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Surrozen, Inc. (SRZN)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Surrozen, Inc. (SRZN)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.